McIntyre, Freedman & Flynn Investment Advisers’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.76M Buy
22,517
+12
+0.1% +$968 1.06% 32
2026
Q1
$1.95M Sell
22,505
-5,275
-19% -$505K 1.11% 32
2025
Q4
$2.67M Sell
27,780
-1,100
-4% -$107K 1.68% 21
2025
Q3
$2.75M Sell
28,880
-100
-0.3% -$9.19K 1.65% 22
2025
Q2
$2.53M Buy
28,980
+50
+0.2% +$4.24K 1.78% 20
2025
Q1
$2.6M Sell
28,930
-10
-0% -$895 1.91% 22
2024
Q4
$2.31M Sell
28,940
-625
-2% -$54.1K 1.73% 22
2024
Q3
$2.66M Sell
29,565
-250
-0.8% -$21K 1.9% 20
2024
Q2
$2.35M Hold
29,815
1.69% 24
2024
Q1
$2.6M Buy
29,815
+800
+3% +$68.3K 1.89% 20
2023
Q4
$2.39M Sell
29,015
-2,600
-8% -$198K 1.91% 19
2023
Q3
$2.48M Buy
31,615
+100
+0.3% +$8.37K 2.09% 17
2023
Q2
$2.78M Sell
31,515
-1,000
-3% -$86.1K 2.37% 14
2023
Q1
$2.62M Buy
32,515
+3,350
+11% +$273K 2.23% 18
2022
Q4
$2.27M Buy
+29,165
New +$2.36M 1.88% 25

Other funds holding MDT

McIntyre, Freedman & Flynn Investment Advisers's MDT Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers increased its Medtronic (MDT) stake by 0.05% in Q2 2026, buying an estimated $968 and bringing the position to 22,517 shares worth $1.76M. The position accounts for 1.06% of the portfolio, ranked #32.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in MDT in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.78M in Q2 2023. 1,667 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • McIntyre, Freedman & Flynn Investment Advisers held 22,517 shares of Medtronic worth $1.76M as of Q2 2026.
  • McIntyre, Freedman & Flynn Investment Advisers bought 12 Medtronic shares in Q2 2026, an estimated $968.
  • Medtronic made up 1.06% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #32 holding.
  • McIntyre, Freedman & Flynn Investment Advisers first reported a position in Medtronic in Q4 2022 and has held it in 15 quarters since.
  • McIntyre, Freedman & Flynn Investment Advisers's Medtronic position peaked at $2.78M in Q2 2023.
  • 1,667 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.